Held on 08 February 2018
The Board of SMS Lifesciences India at meeting held on 08 February 2018 has agreed inprinciple for the acquisition of Mahi Drug, subject to conducting due-diligence.Further, the Board has deliberated and deferred the issue of Non Convertible Preference shares or Non Convertible Debentures on preferential basis to the promoter or promoter group.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
